Summary:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-II Study).
Qualified Participants Must:
• Aged 18 to 65 years
•
Must be on 1 to 2 antidepressants for at least 6 weeks
•
Have a BMI 18kg - 30kg
•
Willing and able to commit to meet all study requirments, adhere to both approved ADT and study drug regimen, and complete all assessments and all scheduled visits, per Investigator judgement
Qualified Participants May Receive:
Compensation for time and travel upon qualifications and enrollment into the study.